Comparability of the WAIS and the WAIS—R: A consideration of level of neuropsychological impairment.

Subjects of varying levels of neuropsychological impairment who were administered the revised version of the Wechsler Adult Intelligence Scale (WAIS-R) were found to obtain significantly lower Full Scale, Verbal, and Performance IQs than a comparable group of subjects who were administered the original version (WAIS). Significant main effects for level of impairment were found for all IQ measures irrespective of the Wechsler scale administered. No significant interactions of Scale?×?Level of Impairment were found for any IQ measure. The results provide the first empirical support for neuropsychologists' use of a standard expected difference between WAIS and WAIS-R IQ scores as a baseline for assessing changes in intellectual functioning. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists

Two new classes of potent and selective CRF(1) receptor antagonists are presented. Exploration of general templates 3 and 4 through modifications of the top amine and bottom phenyl substituents led to optimization of the in vitro affinity and pharmacokinetic profiles. The typical alkyl chains present in the top region of CRF(1) antagonists were replaced by substituted heteroaryl moieties, leading to a dramatic improvement of the metabolic stability. This improvement was apparent when the compounds were dosed in vivo: several compounds exhibited low plasma clearance, good oral bioavailability, and high brain penetration. As a consequence of their outstanding pharmacokinetic profiles, these CRF(1) antagonists, as exemplified by compound 4 fi (4-(4-bromo-3-methyl-1H-pyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine), produced a dose-dependent "anxiolytic-like" effect when administered orally, decreasing the vocalization of rat pups.